MinervaX announces that the company has raised DKK 16 million (EUR 2.2 million) for the development of its Group B Streptococcal Vaccine. The financing was a combination of an equity financing led by Novo Seeds, the seed arm of Novo A/S, supported by Sunstone Capital and LF Investment.